Skip to main content

Market Overview

Mid-Afternoon Market Update: NASDAQ Turns Lower; Bank OZK Shares Plummet


Toward the end of trading Friday, the Dow traded up 0.32 percent to 25,460.03 while the NASDAQ declined 0.40 percent to 7,455.54. The S&P also rose, gaining 0.07 percent to 2,770.61.

Leading and Lagging Sectors

On Friday, the consumer staples shares climbed by 2.4 percent. Meanwhile, top gainers in the sector included Procter & Gamble Co (NYSE: PG) up 8 percent, and Nature's Sunshine Products, Inc. (NASDAQ: NATR) up 5 percent.

In trading on Friday, consumer discretionary shares slipped 0.9 percent.

Top Headline

Procter & Gamble Co (NYSE: PG) reported upbeat earnings for its first quarter.

P&G posted quarterly earnings of $1.12 per share on revenue of $16.69 billion. However, analysts were expecting earnings of $1.10 per share on sales of $16.51 billion. P&G reaffirmed its FY19 organic sales growth guidance of 2 percent to 3 percent year over year.

Equities Trading UP

Skechers U.S.A., Inc. (NYSE: SKX) shares shot up 14 percent to $29.77 after the company reported upbeat earnings for its third quarter and issued a strong outlook for the fourth quarter.

Shares of The9 Limited (NASDAQ: NCTY) got a boost, shooting up 114 percent to $3.38. Jie Qin reported a 7.4 percent stake in The9 Ltd as of Sept 4.

Planet Green Holdings Corp. (NYSE: PLAG) shares were also up, gaining 331 percent to $11.51. Planet Green Form 4 filings from Thursday afternoon showed open market purchases of 1.176 million shares of common stock by 2 executives, CEO, Chairman and Chief Strategy Officer.

Equities Trading DOWN

ServiceSource International, Inc. (NASDAQ: SREV) shares dropped 47 percent to $1.38 after the company lowered its sales forecast and disclosed that its CFO Robert Pinkerton will leave the company.

Shares of Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) were down 28 percent to $3.69. Merrimack, which focuses on therapies for biomarker-defined cancer, said it has terminated a study dubbed SHERLOC, which evaluated its MM-121 in combination with docetaxel in patients with heregulin-positive non-small cell lung cancer, or NSCLC. Docetaxel is a chemotherapy medication used to treat several cancers, including breast cancer, head and neck cancer, prostate cancer and NSCLC. The decision was made after the Independent Data Safety Monitoring Board that evaluated the data from the Phase 2 trial found that the addition of MM-121 to docetaxel did not improve progression-free survival over docetaxel alone in the patient population.

Bank Ozk (NASDAQ: OZK) was down, falling around 28 percent to $25.20 after the company reported weak earnings for its third quarter.


In commodity news, oil traded up 0.64 percent to $69.09 while gold traded down 0.03 percent to $1,229.70.

Silver traded up 0.28 percent Friday to $14.645, while copper rose 1.22 to $2.78.


European shares closed mostly lower today. The eurozone’s STOXX 600 dropped 0.12 percent, the Spanish Ibex Index rose 0.03 percent, while Italy’s FTSE MIB Index slipped 0.04 percent. Meanwhile the German DAX dropped 0.31 percent, and the French CAC 40 declined 0.63 percent while U.K. shares rose 0.32 percent.


U.S. existing home sales declined 3.4 percent at an annual rate of 5.15 million for September. However, economists were expecting a 5.34 million rate.

The total number of active U.S. oil rigs rose by 4 to 873 rigs this week, Baker Hughes Inc reported.



Related Articles (NATR + MACK)

View Comments and Join the Discussion!

Posted-In: Mid-Afternoon Market UpdateNews Eurozone Commodities Global Intraday Update Markets

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at